IDP-122 not checked
Bausch Health Americas, Inc. · HP 0.01%
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Psoriasis
- Main trialPhase 4
- “This study is to evaluate the safety, the systemic exposure of halobetasol propionate (HP), and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-122 lotion in pediatric participants with moderate to severe plaque psoriasis.”In the company’s words, NCT03987763 on ClinicalTrials.gov
- Other names
- HP 0.01%
Other drugs for Psoriasis
- ZasocitinibTakeda · Phase 3
- TQH3906Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Phase 3
- BimekizumabUCB Biopharma SRL · Phase 3
- PiclidenosonCan-Fite BioPharma · Phase 3
- Total coumarin creamPsoriasis Research Institute of Guangzhou · Phase 3
- RisankizumabAbbVie · Phase 3
Coming up1
- NovPhase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Active, not recruiting | Nov 2026 | A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis | |
| Phase 3Completed | 15 Mar 2017 | Safety and Efficacy of IDP-122 in Participants With Plaque Psoriasis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026